I have checked but apologies if this has been posted before.
Published online June 13, 2019.
* In 424 patients with CLL on long-term ibrutinib, AEs were primarily grade 1/2 and manageable; the majority of patients continued therapy.
* AE management requiring dose modification most commonly occurs in the first year of ibrutinib and does not preclude extended therapy.
Lots to read here: bloodadvances.org/content/3...